Progress of inhaled nitric oxide on treatment of persistent pulmonary hypertension of new-born

中国小儿急救医学 Pub Date : 2019-11-20 DOI:10.3760/CMA.J.ISSN.1673-4912.2019.11.011

Chang Liu, Shuqing Zhang, Dongmei Yue

{"title":"Progress of inhaled nitric oxide on treatment of persistent pulmonary hypertension of new-born","authors":"Chang Liu, Shuqing Zhang, Dongmei Yue","doi":"10.3760/CMA.J.ISSN.1673-4912.2019.11.011","DOIUrl":null,"url":null,"abstract":"Persistent pulmonary hypertension is a serious disease among new-borns.Despite the variety of causes, similar physiopathologic changes characterize this syndrome: a persistently raised pulmonary vascular resistance after birth, which leads to severe hypoxemia due to extrapulmonary shunting.The fundamental treatment is to reduce pulmonary vascular pressure and improve hemodynamics.Modern treatments such as inhaled nitric oxide, high-frequency oscillation ventilation, extracorporeal membrane oxygenation, and/or other pulmonary vasodilators could reduce mortality in neonatal persisitent pulmonary hypertension(PPHN). Inhaled nitric oxide is the main method for the treatment of PPHN, which can effectively improve oxygenation and reduce the need for extracorporeal membrane oxygenation(ECMO). The effect of inhaled nitric oxide is different with the gestational age changed.This article aims to summarize the clinical research progress of inhaled nitric oxide in the treatment of PPHN. \n \n \nKey words: \nPersistent pulmonary hypertensionof the newborn; Inhaled nitric oxide; Pulmonary vasodilator substance","PeriodicalId":68901,"journal":{"name":"中国小儿急救医学","volume":"26 1","pages":"858-862"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国小儿急救医学","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-4912.2019.11.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Persistent pulmonary hypertension is a serious disease among new-borns.Despite the variety of causes, similar physiopathologic changes characterize this syndrome: a persistently raised pulmonary vascular resistance after birth, which leads to severe hypoxemia due to extrapulmonary shunting.The fundamental treatment is to reduce pulmonary vascular pressure and improve hemodynamics.Modern treatments such as inhaled nitric oxide, high-frequency oscillation ventilation, extracorporeal membrane oxygenation, and/or other pulmonary vasodilators could reduce mortality in neonatal persisitent pulmonary hypertension(PPHN). Inhaled nitric oxide is the main method for the treatment of PPHN, which can effectively improve oxygenation and reduce the need for extracorporeal membrane oxygenation(ECMO). The effect of inhaled nitric oxide is different with the gestational age changed.This article aims to summarize the clinical research progress of inhaled nitric oxide in the treatment of PPHN. Key words: Persistent pulmonary hypertensionof the newborn; Inhaled nitric oxide; Pulmonary vasodilator substance

查看原文本刊更多论文

吸入一氧化氮治疗新生儿持续性肺动脉高压的研究进展

持续性肺动脉高压是新生儿中一种严重的疾病。尽管病因多种多样，但该综合征具有相似的生理病理变化特征:出生后肺血管阻力持续升高，导致肺外分流导致严重的低氧血症。基本治疗是降低肺血管压力，改善血流动力学。现代治疗如吸入一氧化氮、高频振荡通气、体外膜氧合和/或其他肺血管扩张剂可以降低新生儿持续性肺动脉高压(PPHN)的死亡率。吸入一氧化氮是治疗PPHN的主要方法，可有效改善氧合，减少体外膜氧合(ECMO)的需要。吸入一氧化氮的效果随胎龄不同而不同。本文旨在综述吸入一氧化氮治疗PPHN的临床研究进展。关键词:新生儿持续性肺动脉高压;吸入一氧化氮;肺血管扩张物质

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国小儿急救医学

自引率

0.00%

发文量

6226

期刊介绍： Chinese Journal of Neurology was established in 1955, the predecessor of which is Chinese Journal of Neurology and Psychiatry. Chinese Journal of Neurology and Psychiatry has been indexed by MEDLINE until 1996, when it was divided into two journals, Chinese Journal of Neurology, and Chinese Journal of Psychiatry. Chinese Journal of Neurology is now indexed by EM, SCOPUS, AJ, WPRIM, CNKI, Wanfang Data, CSCD, etc. The impact factor of the journal is 2.755 in 2017, ranking the first among all neurological and psychological journals in China and among all the 142 medical journals published by the Chinese Medical Association. The journal is available both in print and online.